skip to Main Content

Quality of Life and Outcome of Patients with Metastatic Pancreatic Cancer Receiving First‐Line Chemotherapy with Nab‐Paclitaxel and Gemcitabine:

Quality of Life and Outcome of Patients with Metastatic Pancreatic Cancer Receiving First‐Line Chemotherapy with Nab‐Paclitaxel and Gemcitabine:
Few data exists on health‐related quality of life (QoL) in patients with metastatic pancreatic cancer receiving first‐line chemotherapy 1.

The QOLIXANE study is a prospective, non‐interventional, multicenter sub‐study of the Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer (PARAGON) registry, which evaluated QoL in patients with metastatic pancreatic cancer receiving first‐line gemcitabine and nab‐paclitaxel chemotherapy in real‐life setting. Read more . . . .


Back To Top